@article{ATM26175,
author = {Ching-Hui Huang and Chia-Chu Chang},
title = {Vitamin C’s essential role in DNA and histone demethylation and a preclinical rationale for its therapeutic high-dose potential in renal cell carcinoma},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 3},
year = {2019},
keywords = {},
abstract = {Renal cell carcinoma (RCC) accounts for 2–3% of all malignancies in adults and 85% of all cases of adult kidney cancer (1). With an insidious disease course, nearly 25–30% of patients will present with metastatic RCC (2). Otherwise, 30% of patients undergoing nephrectomy progress to distant metastasis or local recurrence during follow-up (3). It is important to be able to predict the risk of early RCC recurrence (4,5). The last two decades have witnessed the development of a number of targeted therapies including tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, but these advancements have largely ignored first-line and subsequent therapies for patients with metastatic RCC (6). It is clear that there is a need for new therapy strategies in advanced RCC.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/26175}
}